Hector Leonardo Montecino Garrido

Dr. Hector Leonardo Montecino Garrido

University of Talca, Talca, Maule, Chile
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2022 in Plants
Verified
Journal Article
Open access
PDF file
LRLyanne Rodríguez
Lyanne Rodríguez
DMDiego Méndez
Diego Méndez
Hector Leonardo Montecino GarridoHector Leonardo Montecino Garrido
Hector Leonardo Montecino Garrido
BCBasilio Carrasco
Basilio Carrasco
BABarbara Arevalo
Barbara Arevalo
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes
In terms of safe and healthy food, beans play a relevant role. This crop belongs to the species of Phaseolusvulgaris L., being the most consumed legume worldwide, both for poor and developed countries, the latter seek to direct their diet to healthy feeding, mainly low in fat. Phaseolus vulgaris L. stands out in this area—an important source of protein, vitamins, essential minerals, soluble fiber, starch, phytochemicals, and low in fat from foods. This species has been attributed many beneficial properties for health; it has effects on the circulatory system, immune system, digestive system, among others. It has been suggested that Phaseolus vulgaris L. has a relevant role in the prevention of cardiovascular events, the main cause of mortality and morbidity worldwide. Conversely, the decrease in the consumption of this legume has been related to an increase in the prevalence of cardiovascular diseases. This review will allow us to relate the nutritional level of this species with cardiovascular events, based on the correlation of the main bioactive compounds and their role as cardiovascular protectors, in addition to revealing the main mechanisms that explain the cardioprotective effects regulated by the bioactive components.

Verified
Journal Article
Open access
PDF file
IPIvan Palomo
Ivan Palomo
FGFrancisco García
Francisco García
CACecilia Albala
Cecilia Albala
SWSERGIO WEHINGER
SERGIO WEHINGER
MFManuel Fuentes
Manuel Fuentes
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes
Background: Frailty has emerged as one of the main geriatric syndromes to be prevented in order to improve quality of health and life in the elderly. In this sense, the characterization of this syndrome through reliable and feasible diagnostic tools for clinical use, such as the Frail Trait Scale 5 (FTS-5) and Frail Trait Scale 3 (FTS-3), represents the basis for this objective. Objectives: To characterize the frailty syndrome in a population of older adults using FTS-5, FTS-3, and Fried phenotype (FP) as frailty diagnostic tools. Design: Cross-sectional study. Participants: 300 adults ≥65 years recruited from different Family Health Centers and community groups of older people in Talca, Chile. Methods: The diagnosis of frailty was made according to FP, FTS-5, and FTS-3 tools. Data about sociodemographic characteristics and anthropometric measurements were collected by a clinical interview by a previously trained health professional. Results: A total prevalence of frailty according to the FP of 19.7% was observed; while in the group of women and men it was 21.4% and 15.0%, respectively. Concerning the FTS-5 tool, the total prevalence of frailty was 18%, while in the group of women and men was 18.0% and 17.5%, respectively. The FTS-3 tool shows a total prevalence of frailty of 23.3%, while in the group of women and men a prevalence of 22.7% and 25.0%, respectively. A significant difference is observed with respect to the presence of the Fried criteria of “weakness” (women: 21.4%, men: 38.8%) and “weight loss” (women: 16.8%, men: 7.5%; p < 0.05). A significant difference is observed concerning the average score of “Handgrip” criteria, “walking time”, and “Physical Activity Scale for the Elderly” (PASE) between the group of women and men. Frailty, diagnosed by FTS-3, is significantly associated with the risk factors of overweight (body mass index ≥ 25) (OR: 10.225, 95% CI: 1.297–80.617) and advanced age (age ≥ 75 years) (OR: 1.839, 95% CI: 1.040–3.250). Conclusion: The prevalence of frailty observed with the FTS-5 (18%) and FTS-3 (23.3%) tools are similar to the prevalence observed through the FP (19.7%) and those reported in other observational studies. Considering the similar prevalence of frailty diagnosed with the three tools, FTS-3 should be a valuable tool for the screening of frailty in the community.

11 May 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Hector Leonardo Montecino GarridoHector Leonardo Montecino Garrido
Hector Leonardo Montecino Garrido
DMDiego Méndez
Diego Méndez
RARamiro Araya-Maturana
Ramiro Araya-Maturana
JMJuan Pablo Millas-Vargas
Juan Pablo Millas-Vargas
SWSergio Wehinger
Sergio Wehinger
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes
Introduction: Obtaining triphenylphosphonium salts derived from anticancer compounds to inhibit mitochondrial metabolism is of major interest due to their pivotal role in reactive oxygen species (ROS) production, calcium homeostasis, apoptosis, and cell proliferation. However, the use of this type of antitumor compound presents a risk of bleeding since the platelet activation is especially dependent on the mitochondrial function. In this study, we evaluated the in vitro effect of three triphenylphosphonium-based compounds, honokiol (HNK), lonidamine (LDN), and atovaquone (ATO), on the platelet function linked to the triphenylphosphonium cation by a lineal 10-carbon alkyl chain and also the decyltriphenylphosphonium salt (decylphos).Methods: Platelets obtained by phlebotomy from healthy donors were exposed in vitro to different concentrations (0.1–10 μM) of the three compounds; cellular viability, exposure of phosphatidylserine, the mitochondrial membrane potential (∆Ψm), intracellular calcium release, and intracellular ROS generation were measured. Platelet activation and aggregation were induced by agonists (adenosine diphosphate, thrombin receptor-activating peptide-6, convulxin, or phorbol-12-myristate-13-acetate) and were evaluated by flow cytometry and light transmission, respectively.Results: The three compounds showed a slight cytotoxic effect from 1 μM, and this was concomitant with a decrease in ∆Ψm and intracellular calcium increase. Only ATO produced a modest but significant increase in intra-platelet ROS. Also, the three compounds increased the exposure to phosphatidylserine in platelets expressed in platelets positive for annexin V. None of the compounds had an inhibitory effect on the aggregation or activation markers of platelets stimulated with three different agonists. Similar results were obtained with decylphos.Conclusion: Triphenylphosphonium derivatives showed slight platelet toxicity below 1 μM, probably associated with their effect on ∆Ψm and exposure to phosphatidylserine, but no significant effect on platelet activation and aggregation, making them an antitumoral alternative with a low risk of bleeding. However, future assays on animal models and human trials are required to evaluate if their effects with a low risk for hemostasis are replicated in vivo.

27 July 2023 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
Hector Leonardo Montecino GarridoHector Leonardo Montecino Garrido
Hector Leonardo Montecino Garrido
MSMagdalena Sepúlveda
Magdalena Sepúlveda
DMDiego Méndez
Diego Méndez
MMMatías Monroy-Cárdenas
Matías Monroy-Cárdenas
SASergio Alfaro
Sergio Alfaro
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes

Verified
Journal Article
Open access
PDF file
Hector Leonardo Montecino GarridoHector Leonardo Montecino Garrido
Hector Leonardo Montecino Garrido
Andrés TrostchanskyAndrés Trostchansky
Andrés Trostchansky
YEYolanda Espinosa-Parrilla
Yolanda Espinosa-Parrilla
IPIvan Palomo
Ivan Palomo
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes
Platelets are small cell fragments that play a crucial role in hemostasis, requiring fast response times and fine signaling pathway regulation. For this regulation, platelets require a balance between two pathway types: the activatory and negative signaling pathways. Activatory signaling mediators are positive responses that enhance stimuli initiated by a receptor in the platelet membrane. Negative signaling regulates and controls the responses downstream of the same receptors to roll back or even avoid spontaneous thrombotic events. Several blood-related pathologies can be observed when these processes are unregulated, such as massive bleeding in activatory signaling inhibition or thrombotic events for negative signaling inhibition. The study of each protein and metabolite in isolation does not help to understand the role of the protein or how it can be contrasted; however, understanding the balance between active and negative signaling could help develop effective therapies to prevent thrombotic events and bleeding disorders.

21 January 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DMDiego Méndez
Diego Méndez
FTFrancisca Tellería
Francisca Tellería
MAMarcelo Alarcón
Marcelo Alarcón
Hector Leonardo Montecino GarridoHector Leonardo Montecino Garrido
Hector Leonardo Montecino Garrido
NGNacim Molina Gutiérrez
Nacim Molina Gutiérrez
Eduardo FuentesEduardo Fuentes
Eduardo Fuentes
Platelet inhibition is a fundamental objective to prevent and treat thrombus formation. Platelet activation depends on mitochondrial function. This study aims to identify a new mitochondria-targeting compound with antiplatelet activity at safe concentrations in vitro. Cytotoxicity and viability tests were performed on human platelets from volunteer donors, together with experiments on aggregation, platelet activation, mitochondrial function, mitochondrial respiration, and thioredoxin reductase 2 (TrxR2) enzymatic activity in isolated platelet mitochondria. The compound MitoCDNB, corresponding to the molecule 5-chloro-2,4-dinitrophenylamino linked with triphenylphosphonium cation (TPP+) by a butyl chain and methanesulfonate as the counterion, was evaluated. MitoCDNB demonstrates potent, high mitochondria-selective antiplatelet effects that provide a novel approach to platelet inhibition with potentially minimized systemic risks. Here, we describe the first compound that inhibits platelet activation by decreasing TrxR2 enzymatic activity and collagen-stimulated maximal mitochondrial respiration, preventing aggregation and platelet activation. These results can be used to develop new antiplatelet drugs targeting mitochondria.